The the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee unanimously recommended a monovalent JN.1-lineage vaccine composition for the fall COVID-19 vaccine formula.
Based on the totality of the evidence, the FDA advised manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines for use in the United States beginning in fall 2024 should be monovalent JN.1 vaccines to more closely match currently circulating SARS-CoV-2 viruses.